RGD-IL-24, a novel tumor-targeted fusion cytokine: expression, purification and functional evaluation.
Targeting drugs to tumor cells is a central challenge for improving existing cancer therapies. ACDCRGDCFCG peptide (RGD-4C) binds to alphavbeta3 integrin, which is selectively expressed in tumor blood vessels and on the surface of some tumor cells. Interleukin 24 (IL-24) is a novel cancer growth-suppressing and apoptosis-inducing cytokine. To enhance the antitumor effect, we coupled RGD-4C to the N-terminus of IL-24 and expressed RGD-IL-24 in Escherichia coli. Cell proliferation and adhesion experiments revealed that RGD-IL-24 specifically binds to MCF-7 cancer cells, and induces apoptosis of MCF-7 cancer cells. These studies support the use of the RGD-IL-24 protein in tumor-targeting therapy.
Xiao
Bin
B
Department of Clinical Microbiology and Immunology, Faculty of Medical Laboratory Science, Third Military Medical University, Chongqing, 400038, People's Republic of China.
Li
Wei
W
Yang
Jun
J
Guo
Gang
G
Mao
Xu-Hu
XH
Zou
Quan-Ming
QM
D002448:Cell Adhesion / Q000502:physiology; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D016503:Drug Delivery Systems / Q000379:methods; D005260:Female; D006801:Humans; D007378:Interleukins / Q000235:genetics / Q000378:metabolism*; D009369:Neoplasms / Q000378:metabolism; D009842:Oligopeptides / Q000235:genetics / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism*; D000099180:Interleukin-24
D007378:Interleukins; D009842:Oligopeptides; D011993:Recombinant Fusion Proteins; D000099180:Interleukin-24; C047981:arginyl-glycyl-aspartic acid